N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis • ClinicalTrials.gov ID: NCT06545331

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Interventions

  • XB010 (Drug)
    IV administration of XB010
  • Pembrolizumab (Drug)
    IV administration of Pembrolizumab

Eligibility criteria

* Age 18 years or older on the day of consent. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * Adequate organ and marrow function. * Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent. * The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer). * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.

Conditions

Locally Advanced or Metastatic Solid Tumors Esophageal Squamous Cell Cancer Head and Neck Squamous Cell Cancer NSCLC (Non-small Cell Lung Cancer) Hormone-receptor-positive Breast Cancer Triple Negative Breast Cancer (TNBC)

Locations

  • City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California, United States
  • UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California, United States
  • Georgetown University Medical Center — Washington D.C., District of Columbia, United States
  • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida, United States
  • Winship Cancer Institute — Atlanta, Georgia, United States
  • University of Chicago Medical Center — Chicago, Illinois, United States
  • Siteman Cancer Center — St Louis, Missouri, United States
  • Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York, United States
  • Carolina BioOncology Institute — Huntersville, North Carolina, United States
  • Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
  • SCRI Oncology Partners — Nashville, Tennessee, United States
  • NEXT Austin — Austin, Texas, United States
  • Baylor University Medical Center — Dallas, Texas, United States
  • University of Texas MD Anderson Cancer Center — Houston, Texas, United States
  • Inova Schar Cancer — Fairfax, Virginia, United States
  • NEXT Virginia — Fairfax, Virginia, United States
  • University Hospitals of Leicester NHS Trust — Leicester, United Kingdom
  • Sarah Cannon Research Institute London — London, United Kingdom
  • University College London Hospitals NHS Foundation Trust — London, United Kingdom
  • The Christie NHS Foundation Trust — Manchester, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record